Research programme: cognitive disorders therapeutics - Cenomed BioSciences

Drug Profile

Research programme: cognitive disorders therapeutics - Cenomed BioSciences

Alternative Names: CB-2,433; CM-2,433; CM-2,450

Latest Information Update: 02 Jul 2010

Price : $50

At a glance

  • Originator Medical College of Georgia
  • Class Small molecules
  • Mechanism of Action Cholinergic receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Alzheimer's disease; Mild cognitive impairment

Most Recent Events

  • 30 Jun 2010 Celgene Corporation to acquire Abraxis BioScience
  • 31 Aug 2007 Preclinical development is ongoing
  • 22 Nov 2004 Preclinical trials in Alzheimer's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top